We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Castle Biosciences (CSTL – Research Report) yesterday and set a price target ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its price objective raised by Leerink Partners from $18.00 to $20.00 in a research report issued to clients and investors on Monday ...

"Although this is the second quarter in a row of disappointing results, we expect 2025+ financial performance and pipeline news flow (specifically oral GLP-1 orforglipron Ph3 results) to be ...

A minor uptick in Leerink Partners’ price target to $87 followed AstraZeneca’s strong third-quarter performance, with revenue reaching $13.565 billion – exceeding projections by 4%.

Leerink Partners served as exclusive financial advisor to Banner and Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor. To find out more about BAFIERTAM, please visit www.bafiertam.com.

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...

In a report released on January 9, Thomas Smith from Leerink Partners reiterated a Buy rating on Climb Bio (CLYM – Research Report). The company’s shares closed last Friday at $2.00.

For IDRx, Centerview Partners LLC is acting as exclusive financial advisor and Goodwin Procter LLP as legal counsel. For GSK, Leerink Partners LLC is acting as the exclusive financial advisor.

Leerink Partners served as exclusive financial advisor to Banner and Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor. To find out more about BAFIERTAM, please visit www.bafiertam.com.